No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
UBS Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $61
J.P. Morgan Maintains Incyte(INCY.US) With Hold Rating
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
J.P. Morgan Sticks to Their Hold Rating for Incyte (INCY)
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)